lifestyle.thedishh.com

Author: Ascelia Pharma

Full Year and Q4 Report 2025: FDA Accepts Orviglance NDA for Review

February 7, 2026
Ascelia Pharma Announces Deputy CEO Julie Waras Brogren to Leave the Company

January 21, 2026
Nomination Committee Appointed for AGM 2026 in Ascelia Pharma AB

December 22, 2025